Latham & Watkins Advises Bank Syndicate on Capital Increase of MorphoSys

Latham & Watkins LLP advised the syndicate banks on MorphoSys’ increase of its current share capital from €34,231,943 to €37,655,137 through a full utilization of its authorized capital 2023-II. Shareholders' pre-emptive rights were excluded. The 3,423,194 new ordinary bearer shares with no-par value (Stückaktien) (New Shares) have been placed with institutional investors at a placement price of €30.00 per new share by way of an accelerated bookbuilding, resulting in gross proceeds of approximately €102.7 million.

The New Shares shall be admitted to trading without a prospectus and included in the existing quotation for the Company's shares in the sub-segment of the regulated market with additional post-admission obligations (Prime Standard) on the Frankfurt Stock Exchange and carry full dividend rights as from January 1, 2023. The delivery and the first day of trading of the New Shares is expected to occur on or around December 19, 2023.

The Latham team was led by Frankfurt partners Oliver Seiler and David Rath, with New York partners Nathan Ajiashvili and Alison Haggerty and associates Camilla Kehler-Weiß, Alexandre Maturana, and Angel Marcial.